Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
December 12, 2014 07:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 12, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active,...
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
December 12, 2014 07:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 12, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture...
Oncothyreon to Present at Stifel 2014 Healthcare Conference
November 12, 2014 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare...
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
November 10, 2014 16:05 ET
|
Cascadian Therapeutics, Inc.
SEATTLE and HAMPTON, N.J., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical...
Oncothyreon Reports Third Quarter 2014 Financial Results
November 06, 2014 16:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today reported financial results for the third quarter ended September 30, 2014.
Loss from operations increased to $8.0...
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call
October 30, 2014 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m....